Anne M Suskind1, J Quentin Clemens2, Yun Zhang2, Brent K Hollenbeck2. 1. Department of Urology, University of California, San Francisco, San Francisco, CA. Electronic address: Anne.Suskind@ucsf.edu. 2. Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI.
Abstract
OBJECTIVE: To identify physician-level factors associated with high rates of sacral neuromodulation testing. MATERIALS AND METHODS: We performed a retrospective cohort study using a 20% sample of national Medicare claims to identify physicians who performed sacral neuromodulation procedures between 2005 and 2010. Physician-level rates of device testing were determined based on the number of patients seen for overactive bladder and urinary retention diagnoses in the office in each calendar year. These rates were then used to fit a Poisson model to examine factors associated with high rates of device testing. RESULTS: The number of physicians performing test procedures increased 4-fold from 2005 to 2010. Average rates of test procedures increased from 4.0 to 6.4 procedures per physician per year (P <.001), whereas rates of device implantation remained stable (P = .23). Physicians who had higher rates of device testing were associated with lower rates of device implantation (estimate, -1.76, P <.01). Other predictors of physicians with higher test rates included more recent calendar year, testing done in any setting other than an ambulatory surgery center, gynecology subspecialty, and geographic location in the South and West (all P values <.01). CONCLUSION: Over time, physicians are testing more patients but are not implanting more devices. Additionally, there is an inverse relationship between rates of device testing and implantation, suggesting opportunities to improve efficiency and resource utilization.
OBJECTIVE: To identify physician-level factors associated with high rates of sacral neuromodulation testing. MATERIALS AND METHODS: We performed a retrospective cohort study using a 20% sample of national Medicare claims to identify physicians who performed sacral neuromodulation procedures between 2005 and 2010. Physician-level rates of device testing were determined based on the number of patients seen for overactive bladder and urinary retention diagnoses in the office in each calendar year. These rates were then used to fit a Poisson model to examine factors associated with high rates of device testing. RESULTS: The number of physicians performing test procedures increased 4-fold from 2005 to 2010. Average rates of test procedures increased from 4.0 to 6.4 procedures per physician per year (P <.001), whereas rates of device implantation remained stable (P = .23). Physicians who had higher rates of device testing were associated with lower rates of device implantation (estimate, -1.76, P <.01). Other predictors of physicians with higher test rates included more recent calendar year, testing done in any setting other than an ambulatory surgery center, gynecology subspecialty, and geographic location in the South and West (all P values <.01). CONCLUSION: Over time, physicians are testing more patients but are not implanting more devices. Additionally, there is an inverse relationship between rates of device testing and implantation, suggesting opportunities to improve efficiency and resource utilization.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein Journal: Urology Date: 2003-01 Impact factor: 2.649
Authors: Karin S Coyne; Chris C Sexton; Vasudha Vats; Christine Thompson; Zoe S Kopp; Ian Milsom Journal: Urology Date: 2011-01-22 Impact factor: 2.649
Authors: Anne P Cameron; Jennifer T Anger; Rodger Madison; Christopher S Saigal; J Quentin Clemens Journal: J Urol Date: 2011-01-19 Impact factor: 7.450
Authors: Lisa Rogo-Gupta; Larissa V Rodriguez; Mark S Litwin; Thomas J Herzog; Alfred I Neugut; Yu-Shiang Lu; Shlomo Raz; Dawn L Hershman; Jason D Wright Journal: Obstet Gynecol Date: 2012-11 Impact factor: 7.661
Authors: Anne M Suskind; Rodney L Dunn; Samuel R Kaufman; John O L DeLancey; J Quentin Clemens; John T Stoffel; Brent K Hollenbeck Journal: Surg Innov Date: 2013-04-16 Impact factor: 2.058